ANI Revises Its Expectations Up Following Record Revenues
Analysts Conservative About Company Future Despite Banner Performance
Executive Summary
ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.
You may also be interested in...
Impressive Q2 Performance Drives Further Guidance Raise At ANI
Management at ANI has upped its estimates for the second time this year after another impressive quarter, driven by Cortrophin gel and a strong generics performance.
The Generics Bulletin Top 50, Part Three: Final Firms Enjoy Mixed Fortunes
In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.
Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.